yes exactly every product that is released that is not possible with other materials/technologies (i.e neo, halfpipes, vascucel) is going to highlight the benefits of the ADAPT tech and reinforce Cardiocel's position of best in class with nothing else like it. Market schepticsm will be wiped out. Very well written blog
VacuCel Clinical Literature Review, page-7
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.80 |
Change
0.020(0.20%) |
Mkt cap ! $207.1M | |||
| Open | High | Low | Value | Volume |
| $9.85 | $10.78 | $9.60 | $572.9K | 57.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5627 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 931 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |